Vernon D Rowe

US Patent:

7658913, Feb 9, 2010

Filed:

May 25, 2007

Appl. No.:

11/753883

Inventors:

Vernon D. Rowe - Shawnee KS, US

Assignee:

Verrow Pharmaceuticals, Inc. - Lenexa KS

International Classification:

A61K 49/04

US Classification:

424 943, 424 94

Abstract:

The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising a substituted cyclodextrin, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug.

US Patent:

8192721, Jun 5, 2012

Filed:

Dec 11, 2008

Appl. No.:

12/333168

Inventors:

Vernon D. Rowe - Shawnee KS, US

Assignee:

Verrow Pharmaceuticals, Inc. - Lenexa KS

International Classification:

A61B 5/055

US Classification:

424 932, 424 93, 424 9322

Abstract:

The invention relates to compositions comprising a gadolinium-based contrast agent and a derivatized cyclodextrin. Further provided are methods for reducing the toxicity associated with gadolinium-based contrast agents.

US Patent:

8277779, Oct 2, 2012

Filed:

Dec 18, 2009

Appl. No.:

12/641708

Inventors:

Vernon D. Rowe - Shawnee KS, US

International Classification:

A61K 49/04

US Classification:

424 943, 424 94

Abstract:

The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising an anionically substituted cyclodextrin, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug.

US Patent:

8574551, Nov 5, 2013

Filed:

Aug 23, 2012

Appl. No.:

13/592510

Inventors:

Vernon D. Rowe - Shawnee KS, US

Assignee:

Verrow Pharmaceuticals, Inc. - Lenexa KS

International Classification:

A61K 49/04

US Classification:

424 943, 424 94

Abstract:

The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising an anionically substituted cyclodextrin, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug.

US Patent:

20030008875, Jan 9, 2003

Filed:

Apr 24, 2002

Appl. No.:

10/128947

Inventors:

Vernon Rowe - Kansas City MO, US

International Classification:

A61K038/21
A61K031/525
A61K031/426

US Classification:

514/251000, 424/085400, 514/369000

Abstract:

The present invention is directed to the treatment of multiple sclerosis by periodically administering a high dose of methotrexate at a level sufficiently high to cross the blood brain barrier. The methotrexate administration is accompanied by leucovorin rescue of the periphery. The high dose methotrexate is preferably administered at 1 to 4 month intervals. The periodic high dose methotrexate treatment may be used in conjunction with interim treatments using a therapeutic agent that is effective in treating MS, but does not cross the BBB in cytotoxic amounts. It is contemplated that the method of the present invention may be employed to treat other non-infectious, non-neoplastic inflammatory conditions of the CNS.

US Patent:

20040048871, Mar 11, 2004

Filed:

Sep 9, 2002

Appl. No.:

10/237320

Inventors:

Vernon Rowe - Kansas City MO, US

International Classification:

A61K031/525
A61K038/21

US Classification:

514/251000, 514/002000

Abstract:

The present invention is directed to a method for treating a non-infectious non-neoplastic inflammatory condition of the CNS comprising administering an initial dose of methotrexate to a human host exhibiting a symptom of said condition at a level which is sufficient to cross the blood brain barrier, wherein said human host has not been clinically diagnosed with said condition, or has not been treated with an immunomodulatory agent. The high dose methotrexate treatment is followed by rescue of the periphery with a methotrexate inhibitor that does not cross the blood brain barrier, and administration of a follow-up treatment considered to have therapeutic value for treating said condition.

US Patent:

20070123478, May 31, 2007

Filed:

Nov 22, 2006

Appl. No.:

11/562924

Inventors:

Vernon Rowe - Shawnee KS, US

International Classification:

A61K 31/724
A61K 31/704

US Classification:

514034000, 514058000

Abstract:

The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising an anionically substituted oligosaccharide, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the oligosaccharide is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug.

US Patent:

20110027390, Feb 3, 2011

Filed:

Oct 13, 2010

Appl. No.:

12/903934

Inventors:

Vernon D. Rowe - Shawnee KS, US

Assignee:

VERROW PHARMACEUTICALS, INC. - Lenexa KS

International Classification:

A61K 33/24
A61P 35/00

US Classification:

424649

Abstract:

The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs such as cisplatin. The invention provides compositions comprising a substituted cyclodextrin, cisplatin and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the cisplatin.